Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IB Study of Durvalumab (MEDI4736) With or Without Tremelimumab in Patients With Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens

NCT02537418 is registered in ClinicalTrials.gov with Canadian Cancer Trials Group as lead sponsor.

NCT NCT02537418
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02537418 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IB Study of Durvalumab (MEDI4736) With or Without Tremelimumab in Patients With Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens
Lead sponsor
Canadian Cancer Trials Group
Phase
Phase 1
Overall status
Active, not recruiting
Start date
October 16, 2015
Completion date
December 31, 2026
Enrollment
153 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

solid malignancies